Search research articles
Contact Us
Filters
Showing results (151-160 of 167) with videos related to
Page
of 17
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
Tetsuya Mitsudomi, John V Heymach, Martin Reck, et al.
Annals of Translational Medicine
|
November 26, 2020
Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03)
Wencheng Zhang, Jingjing Zhao, Weiming Han, et al.
The Lancet. Respiratory Medicine
|
October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, et al.
Radiation Oncology (London, England)
|
June 10, 2021
Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China
Xiao Chang, Wei Deng, Xin Wang, et al.
Eclinicalmedicine
|
May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
Zhihao Lu, Li Kong, Buhai Wang, et al.
Med (New York, N.Y.)
|
October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
Qing Zhou, Yan Yu, Ligang Xing, et al.
Advances in Therapy
|
September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study
Ying Cheng, Zhanyu Pan, Lin Wu, et al.
Lancet (London, England)
|
March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Anwen Xiong, Lei Wang, Jianhua Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
Yunpeng Yang, Jie Huang, Tao Wang, et al.
Cancer Communications (London, England)
|
February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
Jing Zheng, Tao Wang, Yunpeng Yang, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 167) with videos related to
Sort By:
Page
of 17
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
Tetsuya Mitsudomi, John V Heymach, Martin Reck, et al.
Annals of Translational Medicine
|
November 26, 2020
Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03)
Wencheng Zhang, Jingjing Zhao, Weiming Han, et al.
The Lancet. Respiratory Medicine
|
October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, et al.
Radiation Oncology (London, England)
|
June 10, 2021
Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China
Xiao Chang, Wei Deng, Xin Wang, et al.
Eclinicalmedicine
|
May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
Zhihao Lu, Li Kong, Buhai Wang, et al.
Med (New York, N.Y.)
|
October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
Qing Zhou, Yan Yu, Ligang Xing, et al.
Advances in Therapy
|
September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study
Ying Cheng, Zhanyu Pan, Lin Wu, et al.
Lancet (London, England)
|
March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Anwen Xiong, Lei Wang, Jianhua Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
Yunpeng Yang, Jie Huang, Tao Wang, et al.
Cancer Communications (London, England)
|
February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
Jing Zheng, Tao Wang, Yunpeng Yang, et al.
Page
of 17